Physician profile
Amanda Perez
NPI 1477762839
$323.19
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.32 · 2020: $65.00 · 2021: $44.16 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $121.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.78 | 2020-2022 | |
| Lilly USA, LLC | $48.98 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $38.96 | 2019-2020 | |
| Viiv Healthcare Company | $23.87 | 2020 | |
| Phadia US INC. | $13.06 | 2021 | |
| Shire North American Group INC | $12.63 | 2019 | |
| Novo Nordisk INC | $10.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.